Remove Hormones Remove Medicine Remove Production
article thumbnail

Mira’s New Menopause Transitions Kit Allows for At-Home Hormone Monitoring

XTalks

Mira, a California-based women’s health technology company, has introduced its Menopause Transitions Kit, a new hormone monitoring kit designed for menopausal women. The at-home device enables women to track key hormone levels, offering real-time insights into the complex hormonal fluctuations associated with perimenopause and menopause.

Hormones 100
article thumbnail

Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin

Pharmaceutical Technology

Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Ghryvelin is used for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare and serious condition, as well as for Childhood Onset Growth Hormone Deficiency (CGHD), if approved.

Hormones 263
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Neurocrine Biosciences’ Crenessity Approved as First New Treatment in Decades for Rare Genetic Disorder CAH

XTalks

CAH is a group of rare genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone and androgens. The most common form of CAH, 21-hydroxylase deficiency, disrupts hormone production, leading to cortisol deficiency and an overproduction of androgens.

Genetics 116
article thumbnail

Dr Reddy’s to buy US generic products portfolio of Mayne Pharma

Pharmaceutical Technology

Dr Reddy’s Laboratories has signed a definitive agreement to buy Australian company Mayne Pharma Group’s US generic prescription product portfolio in a deal valued at approximately $105m. Mayne Pharma’s portfolio to be acquired comprises around 45 commercial products, four pipeline products and 40 approved, non-marketed products.

article thumbnail

Studies connect hormone to breast cancer and uncover potential for novel targeted drugs

Scienmag

Credit: VCU Massey Cancer Center The hormone prolactin has long been understood to play a vital role in breast growth and development and the production of milk during pregnancy.

article thumbnail

Rezvilutamide by Jiangsu Hengrui Medicine for Prostate Cancer: Likelihood of Approval

Pharmaceutical Technology

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics.

Medicine 100
article thumbnail

Rezvilutamide by Jiangsu Hengrui Medicine for Liver Failure (Hepatic Insufficiency): Likelihood of Approval

Pharmaceutical Technology

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. Jiangsu Hengrui has R&D facilities in China, the US, and Japan.

Medicine 100